Development of Preladenant-Based Radiotracers for Imaging A 2A R in Tumors
Journal of Medicinal Chemistry · 2024
DOI: 10.1021/acs.jmedchem.4c01015 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, 2024. Verfasst von Xueyuan Zeng und 13 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Vaccines for Infectious Diseases, Center for Molecular Imaging and Translational Medicine, Xiang An Biomedicine Laboratory, S…. Hauptthemen laut MEDLINE: Receptor, Adenosine A2A, Radiopharmaceuticals. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 38 Literaturangaben. Gefördert von: National Natural Science Foundation of China, National High-Level Hospital Clinical Research Funding.
Abstract (Originalsprache)
Activation of the adenosine 2A receptor (A2AR) can lead to tumor immunosuppression, which results in poor prognosis of immunotherapy. The aim of this study was to design novel 18F-labeled probes ([18F]F-PFP2 and [18F]F-PFP4) to visualize A2AR in the tumor. The uptake of radioprobes in A2AR-negative 4T1 breast tumor was lower than that of A2AR-positive B16F10 melanoma at 1 h p.i. (1.22 ± 0.36% ID/g vs 2.80 ± 0.72% ID/g), 2 h p.i. (1.09 ± 0.20% ID/g vs 2.93 ± 0.76% ID/g) and 3 h p.i. (0.89 ± 0.27% ID/g vs 2.73 ± 0.58% ID/g), respectively. B16F10 lung metastasis models were employed to expand the application scenarios, observing significantly higher uptake of [18F]F-PFP2 in metastatic lesions compared to normal lung tissue (5.55 ± 2.18% ID/g vs 1.89 ± 0.65% ID/g, tumor/lung ratio ∼3). It is given that [18F]F-PFP2 might lay the foundation for establishing an A2AR-targeted imaging evaluation system for tumors, which will provide more precise guidance for personalized treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- State Key Laboratory of Vaccines for Infectious Diseases, Center for Molecular Imaging and Translational Medicine, Xiang An Biomedicine Laboratory, School of Public Health, Xiamen University, Xiamen 361102, China.
- Department of Nuclear Medicine, Fudan University Shanghai Cancer Center, Shanghai 200032, China.
- Theranostics and Translational Research Center, Institute of Clinical Medicine, Department of Nuclear Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences &, Peking Union Medical College,…
ORCID-Profile: Yanjie Wang, Xianzhong Zhang, Zhide Guo
Förderung
- National Natural Science Foundation of China
- National High-Level Hospital Clinical Research Funding
Zitieren
APA
Zeng, X., Liu, H., Huang, G., Wang, Y., Zhou, W., Wang, Y., Chen, X., Cheng, X., Zhuang, R., Li, J., Fang, J., Huang, L., Zhang, X., & Guo, Z. (2024). Development of Preladenant-Based Radiotracers for Imaging A 2A R in Tumors. Journal of Medicinal Chemistry. https://doi.org/10.1021/acs.jmedchem.4c01015
Vancouver
Zeng X, Liu H, Huang G, Wang Y, Zhou W, Wang Y, et al. Development of Preladenant-Based Radiotracers for Imaging A 2A R in Tumors. Journal of Medicinal Chemistry. 2024. doi:10.1021/acs.jmedchem.4c01015
BibTeX
@article{Zeng2024,
author = {Zeng, Xueyuan and Liu, Hongwu and Huang, Guolong and Wang, Yanjie and Zhou, Wuhao and Wang, Yike and Chen, Xuedong and Cheng, Xingxing and Zhuang, Rongqiang and Li, Jindian and Fang, Jianyang and Huang, Lumei and Zhang, Xianzhong and Guo, Zhide},
title = {Development of Preladenant-Based Radiotracers for Imaging A 2A R in Tumors},
journal = {Journal of Medicinal Chemistry},
year = {2024},
doi = {10.1021/acs.jmedchem.4c01015}
}
EUVIMED